ReviewNature reviews. Gastroenterology & hepatology2019
Big data in IBD: a look into the future.
Review in Nature reviews. Gastroenterology & hepatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Diagnostic Accuracy of AI Algorithms in Aortic Stenosis Screening: A Systematic Review and Meta-Analysis.Clinical medicine & research · 2024Pooled it
- Machine Learning-based Prediction Models for Diagnosis and Prognosis in Inflammatory Bowel Diseases: A Systematic Review.Journal of Crohn's & colitis · 2022Pooled it
- Risk stratification of IBD-associated liver disease using routinely collected biomarkers from a large-scale real-world dataset.BMJ open gastroenterology · 2025Observational
- Emerging Therapies in Inflammatory Bowel Disease: A Comprehensive Review.Journal of clinical medicine · 2025Review
- Modifiable Factors Influencing Disease Flares in Inflammatory Bowel Disease: A Literature Overview of Lifestyle, Psychological, and Environmental Risk Factors.Journal of clinical medicine · 2025Review
- Target Trial Emulation: Improving the Quality of Observational Studies in Inflammatory Bowel Disease Using the Principles of Randomized Trials.Inflammatory bowel diseases · 2025Review
- Big data for neuroscience in the context of predictive, preventive, and personalized medicine.The EPMA journal · 2025Review
- Therapeutic application and potential mechanism of plant-derived extracellular vesicles in inflammatory bowel disease.Journal of advanced research · 2025Review
- Proteomic Profiling of Extracellular Vesicles in Inflammatory Bowel Diseases.International journal of molecular sciences · 2025Article
- Identification and Experimental Validation of Oxidative Stress-Related Biomarkers in Ulcerative Colitis Using Machine Learning.Journal of inflammation research · 2025Article
- Gastroenterologists' attitudes and challenges toward treat-to-target strategies in inflammatory bowel disease: a multinational survey.Therapeutic advances in gastroenterology · 2025Article
- A research agenda for GIScience in a time of disruptions.International journal of geographical information science : IJGIS · 2025Article
- Deciphering the Interplay Among Inflammatory Bowel Disease, Gut Microbiota, and Inflammatory Biomarkers in the Risk of Colorectal Cancer.Mediators of inflammation · 2025Article
- Investigating the impact of steroid dependence on gastrointestinal surgical outcomes from UK Biobank.Scientific reports · 2024Article
- Biosimilars in the Era of Artificial Intelligence-International Regulations and the Use in Oncological Treatments.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Article
- Pharmacological induction of autophagy reduces inflammation in macrophages by degrading immunoproteasome subunits.PLoS biology · 2024Article
- Anemoside B4, a new pyruvate carboxylase inhibitor, alleviates colitis by reprogramming macrophage function.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2024Article
- Pathogenesis and precision medicine for predicting response in inflammatory bowel disease: advances and future directions.eGastroenterology · 2024Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Big data methodologies, made possible with the increasing generation and availability of digital data and enhanced analytical capabilities, have produced new insights to improve outcomes in many disciplines. Application of big data in the health-care sector is in its early stages, although the potential for leveraging underutilized data to gain a better understanding of disease and improve quality of care is enormous. Owing to the intrinsic characteristics of inflammatory bowel disease (IBD) and the management dilemmas that it imposes, the implementation of big data research strategies not only can complement current research efforts but also could represent the only way to disentangle the complexity of the disease. In this Review, we explore important potential applications of big data in IBD research, including predictive models of disease course and response to therapy, characterization of disease heterogeneity, drug safety and development, precision medicine and cost-effectiveness of care. We also discuss the strengths and limitations of potential data sources that big data analytics could draw from in the field of IBD, including electronic health records, clinical trial data, e-health applications and genomic, transcriptomic, proteomic, metabolomic and microbiomic data.
Indexed as
Identifiers
30659247What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.